$20 blood test could help diagnose thousands of hepatitis B patients in need of treatment across Africa
London, July 2, 2018
A simple US $20 blood test could help diagnose thousands of patients with hepatitis B in need of treatment in some of Africa’s poorest regions.
Researchers have developed an accurate diagnostic score that consists of inexpensive blood tests to identify patients who require immediate treatment against the deadly hepatitis B virus, which can lead to liver damage or cancer.
The score consists of two simple blood tests: one measuring presence of antigens, proteins produced by the virus; and another for enzymes produced by the liver in response, to accurately assess patients for treatment.
The score was found to be as accurate as existing methods for identifying the patients in need of immediate treatment but at a fraction of the cost, $20 compared to $100-500 for current tests.
It is also far more accessible than existing methods, such as liver biopsy or HBV DNA, a much more complicated blood sample analysis, which require resources and laboratories that are not always accessible in sub-Saharan Africa.
Researchers from Imperial College London and Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, collaborating with the Pasteur Institute in Paris and other African and European institutions, used data from hundreds of hepatitis B patients in The Gambia who were part of the PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa) study.
Clinical data from more than 800 hepatitis B patients, who had been tested through the PROLIFICA programme, were used to develop this new score.
The new diagnostic test, called TREAT-B, was found to accurately identify HBV positive patients who require treatment in 85 percent of cases (called sensitivity), and could accurately identify those who do not need treatment in 77 percent of cases (called the specificity).
The scientists say that further research is needed, but if the test is successful in larger studies it could be used widely to identify patients in need of hepatitis B treatment and refer thousands of people for life-saving treatment. The test could also be developed further to be implemented as a finger-prick test, similar to those used to detect HIV, to get quicker results.
The researchers also discovered that the diagnosis method worked at all stages of the disease – meaning that people in the early stages of liver disease without symptoms could also be screened and identified.
Imperial’s Dr. Maud Lemoine, co-author of the study, said: “These results show that this simple and inexpensive test could be an accurate way to diagnoses patients in need of hepatitis B treatment in countries with limited resources. This could potentially help diagnose and subsequently treat thousands of people across Africa.”
Co-author, Yusuke Shimakawa from the Pasteur Institute said: “Once these results are validated by further studies, they could be potentially integrated into the WHO guidelines and local guidelines – and implemented in daily practice. There is great potential to diagnose more people and improve access to treatment.”
Viral hepatitis is a major global health problem, and in 2013 an estimated 1.45 million people died from the virus. It is the seventh leading cause of death worldwide, and about half of deaths are attributable to the hepatitis B virus infection.
The hepatitis B virus infects around 250 million people worldwide and is transmitted through blood and bodily fluids. In Africa, it is commonly transferred from mother to baby during birth or between children. However, the virus causes no immediate symptoms and can remain undetected in the body for decades until triggering severe complications such as liver damage (cirrhosis) and cancer.
The region most affected by hepatitis B is Sub-Saharan Africa, where around 80 million people are infected.
Notes for editors
The article is “Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa,” by Yusuke Shimakawa, Ramou Njie, Gibril Ndow, Muriel Vray, Papa Saliou Mbaye, Philippe Bonnard, Roger Sombié, Jean Nana, Vincent Leroy, Julie Bottero, Patrick Ingiliz, Gerrit Post, Bakary Sanneh, Ignatius Baldeh, Penda Suso, Amie Ceesay, Adam Jeng, Harr Freeya Njai, and Shevanthi Nayagam (https://doi.org/10.1016/j.jhep.2018.05.024). It appears in the Journal of Hepatology. This article is openly available at https://www.journal-of-hepatology.eu/article/S0168-8278(18)32102-0/fulltext.
PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa), was carried out between December 2011 and January 2014. The initiative was a collaboration between Imperial College London, the Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, The Gambian Ministry of Health and Social Welfare, and the National Public Health Laboratories. The PROLIFICA study in The Gambia was supported by The Gambian Ministry of Health and Social Affairs, the MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, the National Public Health Laboratory, the European Commission (European Community’s Seventh Framework Program, FP7 grant 265994) and the Gilead Sciences (USA) for providing tenofovir treatment. The study in Senegal was supported by the Agence National de Recherche sur le Sida et les Hépatites Virales (ANRS).
About the Journal of Hepatology
The Journal of Hepatology is the official journal of the European Association for the Study of the Liver (EASL). It publishes original papers, reviews, case reports, and letters to the Editor concerned with clinical and basic research in the field of hepatology. www.journal-of-hepatology.eu
In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy. www.easl.eu
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
International Communications Officer
+44 (0)20 7594 9531